Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 57Carcinoma, Non-Small-Cell Lung 29Breast Neoplasms 18Rectal Neoplasms 14Ovarian Neoplasms 14Carcinoma, Hepatocellular 10Neoplasm Metastasis 9Glioblastoma 9Colonic Neoplasms 9Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 7Fallopian Tube Neoplasms 7Brain Neoplasms 6Neoplasms 5Nasopharyngeal Carcinoma 5Lung Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Liver Neoplasms 4Inflammatory Breast Neoplasms 4Colorectal Cancer Metastatic 4Carcinoma, Ovarian Epithelial 4Stomach Neoplasms 3Pleural Effusion, Malignant 3Meningeal Carcinomatosis 3Melanoma 3Kidney Neoplasms 3Glioma 3Non-squamous Non-small Cell Lung Cancer 2Liver Metastasis Colon Cancer 2

Interventions

tremelimumab 1durvalumab 1Injections 1Docetaxel 1Bevacizumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Platinum-resistant Recurrent Ovarian Cancer × Bevacizumab × Clear all
NCT05325229 2022-10-13

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Unknown
94 enrolled
Gynecologic

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡